Jane Meisel

8PUBLICATIONS

33CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersTumour immunologyPopulation trends and policies

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|Jun 01, 2026

Antibody-drug conjugates in breast cancer.

|Dec 29, 2025

OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy.

Barbara Pistilli, Meritxell Bellet Ezquerra, Lucia Del Mastro

|Aug 25, 2025

Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.

Lorenzo Gerratana, Carolina Reduzzi, Yue Ren

|Jan 29, 2024

High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy.

Sarah J Wood, Yuan Gao, Ji-Hoon Lee

|Nov 08, 2022

When the personal becomes political: The impact of the Dobbs decision on women with cancer.

Jane Lowe Meisel, Amy Harrington, Natalie Whaley

|Apr 22, 2021

We have to talk about it: Bringing fertility into the conversation for young women with breast cancer.

Caitlin E Taylor, Jane Lowe Meisel

Pageof 2

Frequent Collaborators

Ruth M O'Regan

Caitlin E Taylor

Lorenzo Gerratana

Carolina Reduzzi

Yue Ren

Rinath Jeselsohn

Reshma L Mahtani

Cynthia X Ma

Angela DeMichele

Kathy Miller

Frequent Collaborators

Ruth M O'Regan

Caitlin E Taylor

Lorenzo Gerratana

Carolina Reduzzi